Prof. Yoel Kloog, dean of TAU's Faculty of Life Sciences has found a drug compound that is showing positive results in the treatment of pancreatic cancer. Keep in mind, these are Phase I/II trials but the results so far show extended life and virtually none of the toxic side effects usually associated with treatment.
The compound, Salirasib is added to gemcitabine, the drug usually used to treat pancreatic cancer. The drug works by inhibiting the Ras protein which is activated in approximately a third of cancers. Salirasib blocks the formation of groups of Ras cells from forming and multiplying to excessive amounts.
If you want to read more about Salirasib there's more information at Red Orbit.